Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody.
about
Future perspectives in target-specific immunotherapies of myasthenia gravisCrystal structure of Streptococcus pyogenes EndoS, an immunomodulatory endoglycosidase specific for human IgG antibodiesImmune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodiesTreatment of neuromyelitis optica: state-of-the-art and emerging therapiesOptic neuritis in neuromyelitis optica.Neuromyelitis optica: clinical features, immunopathogenesis and treatment.Mechanisms of Autoantibody-Induced Pathology.Aquaporins: important but elusive drug targets.Biology of AQP4 and anti-AQP4 antibody: therapeutic implications for NMO.The treatment of neuromyelitis optica.Neuromyelitis optica pathology in rats following intraperitoneal injection of NMO-IgG and intracerebral needle injury.Inhibitor(s) of the classical complement pathway in mouse serum limit the utility of mice as experimental models of neuromyelitis optica.Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).The intrinsic pathogenic role of autoantibodies to aquaporin 4 mediating spinal cord disease in a rat passive-transfer modelBacterial glycosidases in pathogenesis and glycoengineering.Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid.Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinaseTherapeutic potential of deglycosylated antibodies.Aquaporin water channels in the nervous system.Liquid-liquid diffusion crystallization improves the X-ray diffraction of EndoS, an endo-β-N-acetylglucosaminidase from Streptococcus pyogenes with activity on human IgGImmunotherapy of neuromyelitis optica.Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica.C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica.Unique neuromyelitis optica pathology produced in naïve rats by intracerebral administration of NMO-IgGMarked central nervous system pathology in CD59 knockout rats following passive transfer of Neuromyelitis optica immunoglobulin G.A clinical and radiological profile of neuromyelitis optica and spectrum disorders in an Indian cohort.Novel advances in the diagnosis and treatment of neuromyelitis optica: is there a need to redefine the gold standard?B cells in MS and NMO: pathogenesis and therapy.Therapeutic options in neuromyelitis optica spectrum disorders.Aquaporins in Nervous System.Monoclonal antibody therapy for neuromyelitis optica spectrum disorder: current and future.What Is the Optimal Sequence of Rescue Treatments for Attacks of Neuromyelitis Optica Spectrum Disorder?Toward Clinical use of the IgG Specific Enzymes IdeS and EndoS against Antibody-Mediated Diseases.Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis optica.Neuromyelitis optica spectrum disorders and pregnancy: Interactions and management.Elevated Plasma Chemokines for Eosinophils in Neuromyelitis Optica Spectrum Disorders during Remission.Treatment strategies for neuromyelitis optica
P2860
Q26776225-EDFA87AA-8B4F-44C7-90BF-F4A0721DC682Q27683509-CC32C67D-4D17-402C-AC7A-2FC884CD2B5EQ28069362-B87656BD-6262-4389-B64A-280B147EFA5CQ28245749-B387FED2-909A-4AB3-8269-04EDD6ADAEC9Q30610471-FE683D43-2BAA-470E-9B27-4CCBA1FF7989Q30785267-40CEE789-13F5-4E3F-BE1F-0A7B616F61EBQ33740580-B115EE78-55BB-4205-BA24-1C16DD6268EBQ33792739-C381E032-4967-45E9-8423-9582A56AF31AQ34377212-93E5AE4F-7FED-4A8E-9995-5901F509237FQ34399291-8B021A7E-CEAD-4FB4-80EC-AA90173146B7Q34529121-717AEC2E-6741-40BF-B81A-0E0B2DEB132AQ35013113-6C2851AE-9F91-4949-8254-34B26C712C33Q35052199-4A989AFF-ACE1-4E52-A363-6112CDE92F43Q35242214-C53B062D-BADA-4A46-848C-7CF4A175FCBDQ35362348-87863281-CFDB-4EC5-A685-5AC9F3FC0DC5Q35873009-2858B772-AC07-4D94-AAA3-63AC7721B27EQ36852554-758D5076-3E7B-45BB-AD18-56C4065980FBQ36950457-3E56B5DA-ABA9-4370-B493-1AB93848F582Q37066291-6E3FE1A7-F182-44B8-8471-B8AE0777A357Q37374699-266B0561-6288-4332-BD1F-391324923683Q37456974-3DC4E50B-E70D-4DF6-B692-50E92ADA69F9Q37472990-1FD8D6F6-FCD9-4A7B-9B8B-A048AE3F7EB6Q37615906-9A6F4F86-3F51-49CC-B9ED-52E4647844FBQ37638498-2D042B19-A394-4DA8-9580-786C34FB95B1Q37650971-95EEDF07-887B-4401-9B78-A1BAE8B657D4Q37712153-CA3EE608-2D86-4AC2-BFA3-EB55D13C09F2Q38152822-6F237E9F-6B6E-43E0-9BB4-7C666B2EE3E6Q38212081-75566CCE-159E-43DF-8C7E-9E28748CEB70Q38721559-995C7E61-DF9C-4F39-81D9-01046006B54BQ38750890-5FD01DD9-F9E5-43D7-830E-D994CB88520EQ38816869-A991A7DC-1071-4FFA-924B-4403AEA380D9Q40314562-62074202-59C9-4956-9632-8FCC903A9133Q40425520-C79AC881-5E67-40C2-A4D8-92FA91FE21B2Q46591339-0CA6BB89-E17E-42F8-BF46-F962896B91BAQ49873825-417E5A40-5801-4D46-85C0-8A79F271922AQ52678032-2793904C-A28E-4EAF-9F09-7B1E68C245FAQ57298520-F018A030-6646-4D6C-A1BB-E77B118173DD
P2860
Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Enzymatic deglycosylation conv ...... n G into therapeutic antibody.
@ast
Enzymatic deglycosylation conv ...... n G into therapeutic antibody.
@en
type
label
Enzymatic deglycosylation conv ...... n G into therapeutic antibody.
@ast
Enzymatic deglycosylation conv ...... n G into therapeutic antibody.
@en
prefLabel
Enzymatic deglycosylation conv ...... n G into therapeutic antibody.
@ast
Enzymatic deglycosylation conv ...... n G into therapeutic antibody.
@en
P2093
P2860
P356
P1433
P1476
Enzymatic deglycosylation conv ...... in G into therapeutic antibody
@en
P2093
A S Verkman
Lukmanee Tradtrantip
P2860
P356
10.1002/ANA.23741
P50
P577
2012-10-10T00:00:00Z